CryoCor Reports Publication In Circulation For Treatment Of Atrial Fibrillation

CryoCor, Inc. (Nasdaq:
CRYO), a medical device company focused on the treatment of cardiac
arrhythmias, announced the publication of a European study of atrial
fibrillation patients treated with CryoCor's Cardiac Cryoablation System.
The purpose of the study was to evaluate the role of atrial flutter in the
recurrence of atrial fibrillation and the effectiveness of an ablation
strategy focused on isolating the pulmonary veins to treat the atrial
fibrillation. The study was published in the December 11, 2007 issue of
Circulation.



The 98-patient study was conducted by Dr. Wendel Moreira, Dr. Luz-Maria
Rodriguez, Dr. Carl Timmermans and others in Academic Hospital Maastricht
using CryoCor's Cardiac Cryoablation System. The study prospectively
evaluated the best catheter ablation strategy in patients with paroxysmal
atrial fibrillation with and without concomitant right atrial flutter.
During follow-up averaging 26 months, the authors found that electrical
isolation of the pulmonary veins by catheter ablation was successful in
patients without concomitant atrial flutter at an 82% success rate. In
patients with concomitant atrial flutter, the combination of ablation for
atrial flutter and pulmonary vein isolation alone to treat atrial
fibrillation was frequently insufficient in preventing recurrences of
atrial fibrillation (recurrence rate of 67%). The authors concluded that
those patients with atrial flutter and atrial fibrillation may require
additional sites of ablation to effectively treat their atrial
fibrillation.



Dr. Rodriguez, senior author of the study, stated, "This is the first
time that an ablation strategy for paroxysmal atrial filbrillation and
atrial flutter has been systematically studied. This has implications for
the tools that a clinician may use to treat these atrial arrhythmias. Based
on this study, we do not believe that it will be sufficient to simply
isolate the pulmonary veins in a significant proportion of patients."



About CryoCor



CryoCor is a medical technology company that has developed and
manufactures a disposable catheter system based on its proprietary
cryoablation technology for the minimally invasive treatment of cardiac
arrhythmias. The Company's product, the CryoCor Cardiac Cryoablation
System, or the Cryoablation System, is designed to treat cardiac
arrhythmias through the use of cryoenergy, or extreme cold, to destroy
targeted cardiac tissue. The Cryoablation System has been approved in
Europe for the treatment of atrial fibrillation, and atrial flutter, the
two most common and difficult to treat arrhythmias, since 2002. In the
United States, CryoCor is conducting a pivotal trial to evaluate the safety
and efficacy of the Cryoablation System for the treatment of atrial
fibrillation and the Cryoablation System has been approved for the
treatment of right atrial flutter. For more information please visit the
Company's website at cryocor



Forward Looking Statements



The statements in this press release that are not descriptions of
historical facts are forward-looking statements that are subject to risks
and uncertainties. These include statements related to the study's results
and conclusions drawn from the study's results, all of which are
prospective. Such statements are only predictions and reflect CryoCor's
expectations and assumptions as of the date of this press release based on
currently available operating, financial, and competitive information. The
actual events or results may differ materially from those projected in such
forward-looking statements due to a number of factors, including risks
involved with CryoCor's technology and the diagnosis and treatment of
atrial arrhythmias; risks associated with the Company's dependence on
patents and proprietary rights; risks associated with the Company's
protection and enforcement of its patents and proprietary rights; risks
associated with the development or availability of competitive products or
technologies; risks associated with the Company's ability to maintain and
achieve milestones under collaborative agreements and the other risks and
uncertainties identified in the Company's filings with the Securities and
Exchange Commission. These forward-looking statements speak only as of the
date hereof. The Company expressly disclaims any intent or obligation to
update any of these forward-looking statements.


CryoCor, Inc

cryocor


Buy Anti Flu Face Mask Without Prescription